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EDITORIAL COMMENT
A Small Step for Man,
a Leap Forward for
Postoperative Management*
Allan S. Jaffe, MD, FACC
Rochester, Minnesota
The European Society of Cardiology/American College of
Cardiology (ESC/ACC) redefinition of acute myocardial
infarction (MI), with its move to a troponin standard (1,2)
and particularly the idea that even minor elevations of
troponin with contemporary assays are indicative of risk, has
been slow to be embraced. This is related in part to a lack of
data, in part to a lack of understanding, and, in some
instances, to difficulties with the assays themselves. This
investigator has spoken out about several of these issues in
other venues (3,4). A substantial amount of re-education of
the cardiovascular population about how to appropriately
use troponin is necessary and has, in my estimation, been
lacking. However, large clinical trials in patients with acute
coronary syndromes, despite the reluctance of clinical trial
groups to accept the recommendations (3), have made it
clear that any elevation of troponin is indicative of increased
risk (5,6). This has led to a variety of studies defining new
therapies and the efficacy of such therapies predicated on
troponin markers (7,8).
See page 1547
In other areas, however, the idea that minor elevations are
of importance has been slower to evolve. This is the case
with perioperative MI. However, in this issue of the Journal,
Landesberg et al. (9) from Israel break new ground in this
important area. For the first time, the investigators examine
with contemporary assays very low levels of troponin and
demonstrate that there is a substantial increase in risk when
even minor elevations occur in patients who have undergone
vascular surgery. The Landesberg et al. (9) study builds on
the initial studies utilizing troponin, which used very low
levels.
The first study, published in the New England Journal of
Medicine (10), used a value of 3.1 g/ml, which at the time
for that research assay was at the upper limit of the reference
range for hospitalized controls. This value was extrapolated
to a subsequent value of 0.6 g/ml when the assay was
commercialized (11), just about the 10% coefficient of
variation (CV) level utilized in the study by Landesberg et
al. (9). The studies by Lee and Goldman (12,13) utilized 0.2
g/ml or 0.1 g/ml depending upon the assay for cardiac
troponin T (cTnT), which also, at that time, was the lowest
level that could be measured accurately and presaged the
results reported by Landesberg et al. (9). These initial data,
however, were not pursued with these low cutoff values. Part
of this may be related to the fact that many individuals did
not understand that the 3.1 g/ml value had changed to 0.6
g/ml when the assay was commercialized. Most studies, as
in the earlier one by Landesberg et al. (14), utilized this
artificially high cutoff value (five times the upper limit of the
reference range) or a value of 1.5 g/ml, which is known as
the receiver operator curve for MI cutoff and which pro-
mulgates a criteria close to that which would be the
equivalent for elevations in creatine kinase-MB fraction
(CK-MB). Not surprisingly, these studies demonstrated
that patients with such marked elevations often met criteria
for ischemia utilizing continuous electrocardiographic
(ECG) monitoring and had an adverse short-term progno-
sis. Patients with substantial-sized MIs should be expected
to have an adverse prognosis. Indeed, the present dataset
corroborates this finding as well (see subsequent text).
Given the data that any increase in troponin has prog-
nostic importance and the recommendations of the ESC
and ACC committee that any value over the 99th percentile
of the normal range should be considered abnormal (1,2),
Landesberg and colleagues, when asked, tested what is
known as the 10% CV level. This is a level close to the 99th
percentile but a level where the variability of the assays are
sufficiently good to preclude analytic false positives. Several
of us have advocated the use of this value until the assays
improve (3). These cutoff values are close to those used in
studies done in patients with acute coronary syndromes.
The data presented by Landesberg et al. (9) are impres-
sive. They first demonstrate that only 3.6% of patients
present with symptoms that might alert the clinician to a
possible MI, and only 5.6% would have met the prior World
Health Organization criteria for acute MI. Despite these
facts, patients with low-level elevations of troponin (107 of
the 447 patients or 23.9%) had an adverse prognosis with a
subsequent cardiovascular event over a mean follow-up
period of 32.3 months. Whether one calls these individuals
“patients with acute myocardial infarction” or simply “at
risk,” the improvement in the ability to detect risk was
increased five-fold. Second, and importantly, a relationship
existed between the finding of ischemia with continuous
ECG monitoring and elevations of troponin. Those with
greater elevations tended to have more prolonged ischemia,
but the relationship between troponin elevations of any
degree and ECG ischemia was substantial, suggesting that
the elevations found were indicative of ischemic heart
disease in this population. Finally, Landesberg et al. showed
that the larger the increment in troponin, the more likely an
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Mayo Clinic and Graduate Medical School, Rochester, Minnesota. Dr.
Jaffe is a consultant and receives research support from Dade-Behring, Roche, and
Beckman-Coulter. He is also a consultant to Ortho Diagnostics. All these companies
make troponin assays.
Journal of the American College of Cardiology Vol. 42, No. 9, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Inc. doi:10.1016/S0735-1097(03)01073-8
event was to occur, in keeping with the established concept
that the larger the elevation, the worse the prognosis. Thus,
the data suggest that, in this group of patients, elevations of
troponin should be treated from the prognostic standpoint
similar to elevations of troponin in patients who present
with acute coronary syndromes. Even low levels of troponin
elevations identify a cohort at markedly increased risk for
subsequent events.
As impressive as the data are, several caveats are appro-
priate.
1. The risk of mortality even in the lowest group, which was
2.15-fold greater, was evaluated over a mean of 32.3
months. It appears from the curves that individuals had
a substantial acute hazard, but these data are not pro-
vided. This is an important consideration because it
would substantially impact on how and when one would
evaluate and perhaps intervene in these patients. These
outcome data should be amplified in additional studies.
2. A second important implication is that the assays utilized
for cTnT and, in this instance, the first-generation Dade
cTnI assay are reasonable contemporary assays. How-
ever, the Dade assay has been replaced by a more
sensitive one, and several newer assays are more sensitive
than this particular one. It must be appreciated that all
assays do not measure the same type or amount of cTnI.
Although it is likely that the principle of using the 10%
CV as a cut-point for analysis for all assays will work
reasonably well (3), one needs to exercise caution and
rigor when attempting to extrapolate the significance of
these data to risks faced by patients in your hospital,
which probably utilizes a different assay for troponin.
3. Finally, this group was composed of 447 vascular surgery
patients. This population of patients reflects a group with
a very high a priori incidence of coronary artery disease
(CAD). Thus, and not unexpectedly, elevations were
correlated with ischemic-looking ST-T-wave changes. It
is very likely that the etiology of most of these elevations
were indicative of MI. Therefore, the most appropriate
evaluation for most of these patients would be an
evaluation for underlying CAD. However, this may not
be the case in other surgical populations. For example, if
this were a population of patients with orthopedic
surgery, many of the more modest elevations might be
due to pulmonary embolism (15). Patients with acute
central nervous system disease can also have cardiac
injury, and there is a strong experimental literature
suggesting that CAD need not be the mechanism (16).
Thus, extrapolation from vascular surgery patients to
other patient groups must be done thoughtfully. It is
likely that elevations associated with ischemic heart
disease found in these other populations will have
similar prognostic importance, but a larger percentage
may be due to other disease entities requiring a different
type of evaluation and imparting different prognostic
implications.
As with any important research advance, this dataset
raises new and important questions. Most of these patients
likely had some preoperative evaluation. One wonders if, in
retrospect, one could have predicted which of these patients
was at risk. If so, perhaps one ought to intervene prior to
surgery in those patients whose surgery was elective. It may
also be, if one could identify these patients preoperatively,
that even if one chooses not to intervene invasively, that
strategies such as the use of beta-blockers might be appro-
priate in reducing the incidence of these small infarctions
(17) and improving prognosis. Finally, the questions of
when the events occurred in each of these groups and
whether all patients should undergo immediate, somewhat
delayed, or more markedly delayed evaluations to assist in
their long-term management need to be delineated. Part of
this delineation will include datasets where, in contrast to
this study (9), there are data concerning the etiology of the
long-term outcomes so that strategies specific to this cir-
cumstance can be crafted.
New standards always require new knowledge. These
data, which break new ground, help the field progress. If
those who work in other areas would take the same
approach of questioning and evaluating the ESC/ACC
criteria in large enough datasets so that longer-term prog-
nosis can be assessed, equivalent progress might be made in
clarifying the importance of similar troponin elevations in
other areas as well. Nonetheless, fields progress slowly. This
is a large baby step in the right direction.
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